Papillary Renal Cell Carcinoma Recruiting Phase 2 Trials for Cabozantinib (DB08875)

IndicationStatusPhase
DBCOND0030667 (Papillary Renal Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03866382Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsTreatment
NCT04071223Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL StudyTreatment
NCT03635892A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaTreatment
NCT03541902Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaTreatment